H
Howard A. Burris
Researcher at Sarah Cannon Research Institute
Publications - 593
Citations - 40779
Howard A. Burris is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 80, co-authored 568 publications receiving 34783 citations. Previous affiliations of Howard A. Burris include American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.
Howard A. Burris,Giuseppe Giaccone,Seock-Ah Im,Todd M. Bauer,Do-Youn Oh,Suzanne F. Jones,Jeffrey L. Nordstrom,Hua Li,David A Carlin,Jan Baughman,Robert Lechleider,Yung-Jue Bang +11 more
TL;DR: The pharmacokinetics, safety and activity data for the expansion cohort and an alternative schedule are described, including responses in patients with refractory breast cancer (BC), and preclinical studies showed enhanced ADCC compared to an unmodified precursor.
Journal ArticleDOI
A phase 1 trial and pharmacokinetic study of RRx-001, a novel ROS-mediated pan-epigenetic agent.
Tony R. Reid,Bryan Oronsky,Jeffrey R. Infante,Howard A. Burris,Curtis Scribner,Susan J. Knox,Janet L. Stephens,Gary Fanger,Jan Scicinski +8 more
TL;DR: This dose-escalation trial investigated safety, DLTs, and PK of RRx-001, the first of a new class of pan-epigenetic anticancer agents, binds hemoglobin and drives RBC-mediated redox reactions under hypoxia, affecting multiple aspects of cancer cell-cycle regulation and survival.
Journal ArticleDOI
cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).
Hui K Gan,Jason D. Lickliter,Michael Millward,Yi Gu,SU Weiguo,Chuan Qi,Hua Mu,Melanie M. Frigault,Shethah Morgan,Humphrey Gardner,Laurence Albiges,Sumanta K. Pal,Howard A. Burris,Toni K. Choueiri +13 more
TL;DR: AZD6094 (HMPL-504/volitinib) is a potent, selective Met inhibitor that inhibits in vitro growth of MET-amplified gastric and lung cell lines and induces regressions in PRCC explant models.
Journal ArticleDOI
Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).
Lowell L. Hart,José Baselga,Hope S. Rugo,Shinzaburo Noguchi,Kathleen I. Pritchard,Howard A. Burris,Martine Piccart-Gebhart,Janice F. Eakle,Hirofumi Mukai,Hiroji Iwata,Mona El-Hashimy,Shantha Rao,Ashok Panneerselvam,Tanya Taran,Gabriel N. Hortobagyi,Tarek Sahmoud,David Lebwohl,Michael Gnant +17 more
TL;DR: Exploratory analyses in BOLERO-2 evaluated the effects of EVE vs placebo (PBO) on BM levels and BC progression in bone in pts with bone mets at baseline, andBone turnover markers were exploratory endpoints analyzed at 6 and 12 wks after treatment initiation.
Proceedings ArticleDOI
Abstract B137: Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC‐0980: Initial phase I evaluation
Andrew J. Wagner,Howard A. Burris,Johann S. de Bono,Gordon C Jayson,Johanna C. Bendell,Carlos Gomez-Roca,Saoirse Dolly,Ying-Kiat Zee,Joseph A. Ware,Yibing Yan,K. E. Mazina,Mika K. Derynck,S. N. Holden,Jean-Charles Soria +13 more
TL;DR: GDC‐0980 is a potent, oral, dual PI3K/mTOR inhibitor with promising preclinical activity and no significant toxicities have been observed to date in these ongoing Phase I studies at exposures producing PD modulation in surrogate tissue and tumor.